Lynda M Vrooman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL
    Lynda M Vrooman
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, 02215, USA
    J Clin Oncol 31:1202-10. 2013
  2. doi request reprint Childhood acute lymphoblastic leukemia: update on prognostic factors
    Lynda M Vrooman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Pediatr 21:1-8. 2009
  3. pmc Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia
    Lynda M Vrooman
    Department of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Pediatr Blood Cancer 54:199-205. 2010
  4. pmc The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium
    Lynda M Vrooman
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 47:1373-9. 2011
  5. pmc Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia
    Lewis B Silverman
    Departments of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:1351-3. 2010
  6. doi request reprint Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
    Elly V Barry
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1106-11. 2008
  7. doi request reprint Health status of the oldest adult survivors of cancer during childhood
    Lisa B Kenney
    Department of Hematology Oncology, Children s Hospital, Boston, Massachusetts, USA
    Cancer 116:497-505. 2010

Detail Information

Publications7

  1. pmc Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL
    Lynda M Vrooman
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, 02215, USA
    J Clin Oncol 31:1202-10. 2013
    ..We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL)...
  2. doi request reprint Childhood acute lymphoblastic leukemia: update on prognostic factors
    Lynda M Vrooman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Pediatr 21:1-8. 2009
    ..This review highlights recent advances in our understanding of prognostic factors that may be used to refine risk group classification...
  3. pmc Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia
    Lynda M Vrooman
    Department of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Pediatr Blood Cancer 54:199-205. 2010
    ..We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase-allergic patients...
  4. pmc The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium
    Lynda M Vrooman
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 47:1373-9. 2011
    ..We determined the incidence of SMNs in children and adolescents with acute lymphoblastic leukaemia (ALL) who were treated with dexrazoxane...
  5. pmc Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia
    Lewis B Silverman
    Departments of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:1351-3. 2010
    ..This trial was registered at www.clinicaltrials.gov as #NCT00400946...
  6. doi request reprint Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
    Elly V Barry
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1106-11. 2008
    ..We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01...
  7. doi request reprint Health status of the oldest adult survivors of cancer during childhood
    Lisa B Kenney
    Department of Hematology Oncology, Children s Hospital, Boston, Massachusetts, USA
    Cancer 116:497-505. 2010
    ..Young adult survivors of childhood cancer have an increased risk for treatment-related morbidity and mortality. In this study, the authors assessed how treatment for childhood cancer affects older-adult health and health practices...